- Home
- PEPG
PEPG
PepGen Inc.
as 04-01-2025 3:41pm EST
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | N/A | IPO Year: | 2022 |
| Target Price: | $10.33 | AVG Volume (30 days): | 437.7K |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.85 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.16 - $19.30 | Next Earning Date: | 05-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of PepGen Inc. (PEPG)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Donnelly Noel | PEPG | Chief Financial Officer | Feb 24 '25 | Sell | $1.68 | 1,527 | $2,565.36 | 1,673 | |
| DeLena Mary Beth | PEPG | General Counsel | Feb 24 '25 | Sell | $1.68 | 1,432 | $2,405.76 | 1,568 |
Latest PepGen Inc. News
PEPG Breaking Stock News: Dive into PEPG Ticker-Specific Updates for Smart Investing
Business Wire
2 days ago
PepGen Announces Appointment of Two New Directors to its Board
Business Wire
23 days ago
PepGen Announces Presentations at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
Clinical Trials Arena
a month ago
PepGen pauses Phase II DMD trial to review safety data
MT Newswires
a month ago
PepGen to Pause Study in Duchenne Muscular Dystrophy; Shares Down Pre-Bell
Business Wire
a month ago
PepGen to Participate in Upcoming Investor Conferences
Business Wire
a month ago
PepGen Announces Update to Phase 2 CONNECT2-EDO51 Study in Patients with DMD
Clinical Trials Arena
a month ago
PepGen reports positive initial data from Phase I DM1 therapy trial
MT Newswires
a month ago
Top Midday Gainers
Compare PEPG vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PEPG PepGen Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.